معرفی
Wouter W de Herder is Professor of Endocrine Oncology at Erasmus University Rotterdam's Erasmus School of Medicine, Department of Internal Medicine since 2011. With continuous staff membership since 1991 at Erasmus MC in Rotterdam, he has held leadership roles including Head of Outpatient Endocrinology Clinic (2005-2011) and Head of Endocrinology Clinic (1992-2005).
Professor de Herder received his MD (1985) and PhD (1990) from Erasmus University Rotterdam. His research focuses on neuroendocrine and adrenal tumors, particularly neuroendocrine neoplasms, Cushing's syndrome, and peptide receptor radionuclide therapy. His work bridges clinical practice with historical perspectives in endocrinology.
Analysis of his recent publications reveals a strong emphasis on neuroendocrine tumor diagnostics and treatment, especially peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTATATE for pancreatic and gastrointestinal tumors. His research consistently addresses prognostic markers, symptom control in carcinoid syndrome, and innovative approaches to mesenteric fibrosis complications.
Key scientific recognitions include:
- Dr. Henry Friesen Plenary Award Lecture (2017)
- ESE Annual Special Recognition Award (2018)
- NVE-Novartis Award for Endocrinology (2023)
- Leadership roles in ENETS (Chairman 2006-2008, Advisory Board Chairman 2015-2019)
- Current Chairman of EURACAN Domain 4 for Rare Neuroendocrine Cancers (2021-present)
Professor de Herder has supervised numerous researchers through his leadership in the NVE Academy (Chairman since 2019) and EURACAN. His extensive grant portfolio is evidenced by coordination of the EU European Reference Networks for rare cancers. He serves on editorial boards of Endotext, Nederlands Tijdschrift voor Geneeskunde, Endocrine-related Cancer, and Journal of Neuroendocrinology.
He leads the EURACAN Domain 4 research team focusing on rare neuroendocrine cancers and collaborates with international consortia including ENETS and NANETS. His laboratory work integrates clinical data with radiomics and molecular analysis to predict tumor behavior and treatment response.
